Anti-IL-5 Cuts Exacerbations in Eosinophil Asthma – MedPage Today


Scicasts (press release) (registration) (blog)

Anti-IL-5 Cuts Exacerbations in Eosinophil Asthma
MedPage Today
In one of the studies, the clinical asthma exacerbation (CAE) rate was halved (rate ratio 0.50, 95% CI 0.37-0.67, P<0.0001) among patients receiving reslizumab compared with those given placebo, reported Mario Castro, MD, MPH, of Washington University …
Investigational drug can reduce asthma flareupsMedical Xpress
Investigational biologics among emerging therapies for severe asthmaHealio
Investigational Drug Could Reduce Asthma FlareupsScicasts (press release) (registration) (blog)
MarketWatch
all 13 news articles »

View full post on asthma – Google News

Mepolizumab May Substantially Reduce Asthma Exacerbations – JAMA: The Journal of the American Medical Association

Mepolizumab May Substantially Reduce Asthma Exacerbations
JAMA: The Journal of the American Medical Association
Mepolizumab, a humanized monoclonal antibody against interleukin-5, significantly reduced asthma exacerbations and improved quality of life among patients treated with inhaled glucocorticoids, according to a randomized, placebo-controlled trial with

and more »

View full post on asthma – Google News

Mepolizumab reduces exacerbations in severe eosinophilic asthma [MENSA trial] – 2 Minute Medicine


2 Minute Medicine

Mepolizumab reduces exacerbations in severe eosinophilic asthma [MENSA trial]
2 Minute Medicine
1. The rate of asthma exacerbations was significantly reduced in patients with severe eosphinophilic asthma receiving either intravenous or subcutaneous mepolizumab, compared to patients receiving placebo. 2. The safety profile of mepolizumab was
Seven developments in asthma researchHealio

all 2 news articles »

View full post on asthma – Google News

Teva’s Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies – RTT News

Teva's Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies
RTT News
Teva Pharmaceutical Industries Ltd. (TEVA: Quote) announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma …

and more »

View full post on asthma – Google News

Elevated blood eosinophil levels are a risk factor for asthma exacerbations – EurekAlert (press release)

Elevated blood eosinophil levels are a risk factor for asthma exacerbations
EurekAlert (press release)
ATS 2014, SAN DIEGO ? In adults with persistent asthma, elevated blood eosinophil levels may be able to predict which individuals are at increased risk for exacerbations, according to a new study presented at the 2014 American Thoracic Society …

and more »

View full post on asthma – Google News